BRPI0308103B8 - vacina de dna eficaz para despertar uma resposta imune contra células endoteliais proliferantes, uso de uma construção de dna que codifica operacionalmente uma proteína de receptor de vegf e um veículo farmaceuticamente aceitável desta e artigo de manufatura - Google Patents

vacina de dna eficaz para despertar uma resposta imune contra células endoteliais proliferantes, uso de uma construção de dna que codifica operacionalmente uma proteína de receptor de vegf e um veículo farmaceuticamente aceitável desta e artigo de manufatura

Info

Publication number
BRPI0308103B8
BRPI0308103B8 BRPI0308103A BR0308103A BRPI0308103B8 BR PI0308103 B8 BRPI0308103 B8 BR PI0308103B8 BR PI0308103 A BRPI0308103 A BR PI0308103A BR 0308103 A BR0308103 A BR 0308103A BR PI0308103 B8 BRPI0308103 B8 BR PI0308103B8
Authority
BR
Brazil
Prior art keywords
dna
vegf receptor
dna vaccine
endothelial cells
receptor protein
Prior art date
Application number
BRPI0308103A
Other languages
English (en)
Other versions
BRPI0308103B1 (pt
BR0308103A (pt
Inventor
G Niethammer Andreas
A Reisfeld Ralph
Xiang Rong
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of BR0308103A publication Critical patent/BR0308103A/pt
Publication of BRPI0308103B1 publication Critical patent/BRPI0308103B1/pt
Publication of BRPI0308103B8 publication Critical patent/BRPI0308103B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"vacina de dna contra células endoteliais proliferantes e métodos de uso desta". uma vacina de dna eficaz para inibição de proliferação de célula endotelial que compreende uma construção de dna que codifica operacionalmente uma proteína de receptor de fator de crescimento vascular endotelial (vegf). essa invenção fornece vacinas de dna que codificam receptor-2 de vegf (kdr, id. de seq. nr: 2), receptor-1 de vegf (flt-1, id. de seq. nr: 4), ou flk-l (o homólogo murídeo de kdr, id. de seq. nr: 6), seqüências de dna ids. de seq. nrs: 1, 3, e 5 respectivamente, bem como métodos de uso de tal vacina de dna para inibir proliferação de célula vascular endotelial no microambiente do tumor. é obtida anti-angiogênese e subseqüente diminuição do crescimento e disseminação de tumor.
BRPI0308103A 2002-03-02 2003-02-28 vacina de dna eficaz para despertar uma resposta imune contra células endoteliais proliferantes, uso de uma construção de dna que codifica operacionalmente uma proteína de receptor de vegf e um veículo farmaceuticamente aceitável desta e artigo de manufatura BRPI0308103B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/090.183 2002-03-02
US10/090,183 US7094410B2 (en) 2002-03-02 2002-03-02 DNA vaccine against proliferating endothelial cells and methods of use thereof
PCT/US2003/006256 WO2003073995A2 (en) 2002-03-02 2003-02-28 Dna vaccine against proliferating endothelial cells and methods of use thereof.

Publications (3)

Publication Number Publication Date
BR0308103A BR0308103A (pt) 2005-01-04
BRPI0308103B1 BRPI0308103B1 (pt) 2019-02-19
BRPI0308103B8 true BRPI0308103B8 (pt) 2021-05-25

Family

ID=27787599

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0308103A BRPI0308103B8 (pt) 2002-03-02 2003-02-28 vacina de dna eficaz para despertar uma resposta imune contra células endoteliais proliferantes, uso de uma construção de dna que codifica operacionalmente uma proteína de receptor de vegf e um veículo farmaceuticamente aceitável desta e artigo de manufatura

Country Status (19)

Country Link
US (3) US7094410B2 (pt)
EP (1) EP1487482B1 (pt)
JP (1) JP4598401B2 (pt)
KR (1) KR100979898B1 (pt)
CN (1) CN1293917C (pt)
AT (1) ATE528015T1 (pt)
AU (1) AU2003228229B2 (pt)
BR (1) BRPI0308103B8 (pt)
CA (1) CA2477406C (pt)
CY (1) CY1112663T1 (pt)
DK (1) DK1487482T3 (pt)
ES (1) ES2371870T3 (pt)
MX (1) MXPA04008468A (pt)
PL (1) PL213364B1 (pt)
PT (1) PT1487482E (pt)
RU (1) RU2318019C2 (pt)
SI (1) SI1487482T1 (pt)
WO (1) WO2003073995A2 (pt)
ZA (1) ZA200406988B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1595548A3 (en) * 2001-03-07 2006-02-22 Mannkind Corporation Anti-neovasculature preparations for treating cancer
US7094410B2 (en) * 2002-03-02 2006-08-22 The Scripps Research Institute DNA vaccine against proliferating endothelial cells and methods of use thereof
CU23178A1 (es) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
KR100614220B1 (ko) 2004-11-08 2006-08-21 고려대학교 산학협력단 Ｆｌｔ3 리간드 유전자를 발현하는 살모넬라 균주 및 이를함유하는 항암 치료용 조성물
CN101766818B (zh) * 2008-12-30 2013-05-22 陕西北美基因股份有限公司 多糖金磁复合微粒载药体及其制备方法
WO2010102140A1 (en) * 2009-03-04 2010-09-10 The Trustees Of The University Of Pennsylvania Compositions comprising angiogenic factors and methods of use thereof
US9492523B2 (en) 2011-12-09 2016-11-15 The Board Of Regents For Oklahoma State University Broadly protective Shigella vaccine based on type III secretion apparatus proteins
CA2853656C (en) * 2011-12-22 2020-12-29 Vaximm Ag Method of producing high yield attenuated salmonella strains
JP6325534B2 (ja) 2012-07-05 2018-05-16 バクシム アクチェンゲゼルシャフト 膵臓癌患者用ｄｎａワクチン
JP6422022B2 (ja) 2012-08-31 2018-11-14 国立大学法人大阪大学 Ｖｅｇｆ及び／又はアンギオポエチン−２の特異的エピトープを含むｄｎａワクチン
US10548962B2 (en) 2012-10-22 2020-02-04 The Board Of Regents For Oklahoma State University Use of the salmonella SPP type III secretion proteins as a protective vaccination
US9950053B2 (en) 2012-10-22 2018-04-24 The Board Of Regents For Oklahoma State University Use of the Salmonella SPP type III secretion proteins as a protective vaccination
US20180153976A1 (en) 2015-06-18 2018-06-07 Vaximm Ag Novel cmv pp65 targeting dna vaccine for cancer immunotherapy
RU2018101722A (ru) 2015-06-18 2019-07-18 Факсимм Аг Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии
RU2759227C2 (ru) * 2020-04-10 2021-11-11 Генетик Диагностикс Энд Терапи 21 Лтд ДНК-вакцина против вируса SARS-CoV-2 на основе генотерапевтического ДНК-вектора GDTT1.8NAS12, способ ее получения, штаммы, несущие генотерапевтические ДНК-вектора, способ их получения, способ производства в промышленных масштабах генотерапевтических ДНК-векторов
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214804B1 (en) * 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US6228844B1 (en) * 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US5939400A (en) * 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
RU2177950C2 (ru) * 1996-10-25 2002-01-10 Нексстар Фармасьютикалз, Инк. Комплексы нуклеиновых кислот - лигандов сосудистого эндотелиального фактора роста (vegf)
WO1998058053A1 (en) * 1997-06-18 1998-12-23 Merck & Co., Inc. Human receptor tyrosine kinase, kdr
AU2994599A (en) * 1998-03-06 1999-09-20 Imclone Systems Incorporated Active immunization against angiogenesis-associated antigens
SI1108035T1 (sl) * 1998-09-04 2007-12-31 Sanofi Pasteur Ltd Zdravljenje raka materničnega vratu
WO2002003961A1 (en) 2000-07-07 2002-01-17 Corixa Corporation Microspheres and adjuvants for dna vaccine delivery
US7094410B2 (en) * 2002-03-02 2006-08-22 The Scripps Research Institute DNA vaccine against proliferating endothelial cells and methods of use thereof

Also Published As

Publication number Publication date
SI1487482T1 (sl) 2012-01-31
EP1487482B1 (en) 2011-10-12
KR100979898B1 (ko) 2010-09-06
JP2005519092A (ja) 2005-06-30
JP4598401B2 (ja) 2010-12-15
PL213364B1 (pl) 2013-02-28
US20120039931A1 (en) 2012-02-16
EP1487482A4 (en) 2006-04-12
US20070059323A1 (en) 2007-03-15
RU2004129332A (ru) 2005-05-27
KR20040088573A (ko) 2004-10-16
ATE528015T1 (de) 2011-10-15
US7094410B2 (en) 2006-08-22
CN1649622A (zh) 2005-08-03
US8241637B2 (en) 2012-08-14
WO2003073995A2 (en) 2003-09-12
BRPI0308103B1 (pt) 2019-02-19
CY1112663T1 (el) 2016-02-10
CN1293917C (zh) 2007-01-10
EP1487482A2 (en) 2004-12-22
PT1487482E (pt) 2011-12-29
WO2003073995A3 (en) 2003-11-20
RU2318019C2 (ru) 2008-02-27
AU2003228229B2 (en) 2008-03-06
BR0308103A (pt) 2005-01-04
ES2371870T3 (es) 2012-01-10
AU2003228229A1 (en) 2003-09-16
ZA200406988B (en) 2005-11-30
DK1487482T3 (da) 2011-12-05
US8048428B2 (en) 2011-11-01
US20030185802A1 (en) 2003-10-02
CA2477406A1 (en) 2003-09-12
PL372314A1 (en) 2005-07-11
CA2477406C (en) 2013-10-29
MXPA04008468A (es) 2004-12-06

Similar Documents

Publication Publication Date Title
BRPI0308103B8 (pt) vacina de dna eficaz para despertar uma resposta imune contra células endoteliais proliferantes, uso de uma construção de dna que codifica operacionalmente uma proteína de receptor de vegf e um veículo farmaceuticamente aceitável desta e artigo de manufatura
AU2020203352B2 (en) Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
Kowalczyk et al. Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity
Inderberg et al. T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth
IL259120A (en) Her2-targeted antigen chimeric receptors2
ES2251610T3 (es) Mutantes de interleuquina-18, su produccion y su uso.
CN110437339A (zh) 一种以白介素15为活性成分的融合蛋白型药物前体
CY1113379T1 (el) Πεπτιδια κdr και εμβολια που τα περιλαμβανουν
Jiao et al. A PD-L1 and VEGFR2 dual targeted peptide and its combination with irradiation for cancer immunotherapy
CN109310746A (zh) 过继细胞转移与溶瘤病毒组合疗法
Patel et al. Plasma membrane vesicles decorated with glycolipid-anchored antigens and adjuvants via protein transfer as an antigen delivery platform for inhibition of tumor growth
JP2024150469A (ja) がんの予防または治療方法において使用するためのがん／精巣抗原をコードするウイルスベクター
Chakrabarti et al. Plasmids encoding membrane-bound IL-4 or IL-12 strongly costimulate DNA vaccination against carcinoembryonic antigen (CEA)
CA2480996A1 (fr) Peptides derives ou provenant de cytokine et leur application en therapeutique
KR20070068398A (ko) 재조합 마이코박테리움의 조합물 및 백신과 같은 생물학적활성제
CA2691406C (en) Preprocalcitonin antigen t epitopes
Azad et al. Glioblastoma antigen discovery—foundations for immunotherapy
CN102584943A (zh) 一种血管平滑肌l型钙离子通道免疫原性肽段及其用途
JP2026503536A (ja) 生着中の一過性のｓｔａｔ５ｂ活性化によって媒介されるリンパ球が充足している宿主におけるｔ細胞養子移入
CN105906705A (zh) 一种cd19免疫原多肽及其用途
KR101734637B1 (ko) TgPRF1의 백신강화제로서의 용도
Mamonkin et al. 69. TNFR Costimulatory Domains Impair Expansion of CD5 CAR T Cells Due to Enhanced Fas-Mediated Apoptosis
Bequet-Romero et al. Mutated variant of human vascular endothelial growth factor as a vaccine candidate for cancer immunotherapy
Czink et al. 68. Immunovirotherapy: Enhancing Personalized T Cell Therapy with Oncolytic Measles Virus Vaccination
Boom et al. Generation of T Cell Help through a MHC

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/02/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/02/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/02/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 28/02/2023